NeuroMetrix Reports Q3 2024 Business Highlights

NURO 11.05.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur NURO Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - NeuroMetrix to be Acquired by electroCore
  • 11.05.2024 - NeuroMetrix Reports Q3 2024 Business Highlights

Recent Filings

  • 12.30.2024 - 8-K Current report
  • 12.19.2024 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 12.17.2024 - EX-99.1 EX-99.1
PDF Version
Company Continues to Pursue Review of Strategic Alternatives

WOBURN, Mass.,Nov. 05, 2024(GLOBE NEWSWIRE) --NeuroMetrix, Inc.(Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months endedSeptember 30, 2024. The Company develops proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.NeuroMetrix, Inc.is actively pursuing its previously announced review of strategic options to enhance shareholder value.

Over the past several quarters, the Company has strengthened its Board of Directors, terminated common stock sales under its ATM program, implemented a reduction-in-force, and phased-out its legacy ADVANCE®business. As a result, operating expenses and cash usage have been lowered by over$0.5Mper quarter. The Company continues to build the Quell®Fibromyalgia business via direct-to-physician marketing and sales toVeterans Health Administrationfacilities.

Q3 Business Highlights:

  • Quell revenue increased by 50% to$184,000in Q3 2024 from$123,000in Q3 2023. Quell revenue includes Quell Fibromyalgia (prescription) and Quell Relief (OTC).
  • DPNCheck®revenue of$404,000in Q3 2024 declined by$568,000or 58% from Q3 2023. The primary DPNCheck market, Medicare Advantage (MA), is in the final year of the CMS phase-out of risk-adjustment compensation for many types of patient screening, including peripheral neuropathy. Potential opportunities in alternative markets are being pursued.

Q3 Financial Results:

Revenue in Q3 2024 of$0.6 millionwas lower by$0.6 millionor 51% from Q3 2023. DPNCheck was the primary factor in the decline. Gross profit of$0.3 millionwas down by$0.5 milliondue to the DPNCheck revenue effect, the unfavorable shift in product mix, and lower production volume. Operating expenses of$2.1 millionin Q3 2024, were reduced by$0.7 millionor 25% from the prior year period. The Q3 2024 net loss was$1.5 million, or ($0.75) per share, versus$1.8 million, or ($1.66) per share, in Q3 2023. There were 2.0 million common shares outstanding at the end of Q3 2024 and 1.1 million shares outstanding at the end of Q3 2023.

Revenue of$2.5 millionfor the nine months endedSeptember 30, 2024declined by$2.1 millionor 47% from the comparable period in 2023. Net loss of$6.0 million, or ($3.10) per share, compared with the net loss of$4.9 million, or ($4.86) per share, during the 2023 period.

As ofSeptember 30, 2024, cash, cash equivalents and securities totaled$14.8 million.

The Company believes it is in the best interests of shareholders that the strategic review process continues. There can be no assurance that this process will result in the Company pursuing or consummating any particular transaction or other strategic outcome. The Company has not set a timetable for completion of this evaluation process and may not disclose further developments unless disclosure is appropriate or necessary.

AboutNeuroMetrix

NeuroMetrixis a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell®is a wearable neuromodulation platform. DPNCheck®is a point-of-care screening test for peripheral neuropathy. For more information, visitwww.neurometrix.com.

Safe Harbor Statement

The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s or management’s expectations regarding the business, as well as events that could have a meaningful impact on the company’s revenues and cash resources. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, estimates of future performance, and the ability to successfully develop, receive regulatory clearance, commercialize and achieve market acceptance for any products. There can be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with theSecurities and Exchange Commissionor otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.

Source:NeuroMetrix, Inc.

Thomas T. HigginsSVP and Chief Financial Officerneurometrix.ir@neurometrix.com

NeuroMetrix, Inc.Statements of Operations(Unaudited)
Quarters EndedSeptember 30,Nine Months EndedSeptember 30,
2024202320242023
Revenues$587,314$1,203,164$2,450,018$4,583,679
Cost of revenues275,357421,3821,129,1251,484,240
Gross profit311,957781,7821,320,8933,099,439
Operating expenses:
Research and development299,739592,6541,510,2232,045,588
Sales and marketing441,171943,7951,937,9142,504,630
General and administrative1,313,0951,206,2314,697,4503,843,643
Total operating expenses2,054,0052,742,6808,145,5878,393,861
Loss from operations(1,742,048)(1,960,898)(6,824,694)(5,294,422)
Other income233,822192,161798,962414,482
Net loss$(1,508,226)$(1,768,737)$(6,025,732)$(4,879,940)

NeuroMetrix, Inc.Condensed Balance Sheets(Unaudited)
September 30,2024December 31,2023
Cash, cash equivalents and securities$14,834,600$17,997,151
Other current assets1,961,0902,857,291
Noncurrent assets393,330569,999
Total assets$17,189,020$21,424,441
Current liabilities$1,209,871$1,240,639
Lease obligation, net of current portion-92,485
Stockholders’ equity15,979,14920,091,317
Total liabilities and stockholders’ equity$17,189,020$21,424,441

Primary Logo

Source: NeuroMetrix, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com